Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Contrave for Smoking Cessation in Overweight/Obese Subjects
NCT00563563Phase 2Completed
- Sponsor
- Orexigen Therapeutics
- Start
- Oct 2007
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of naltrexone + bupropion in nicotine dependence, obesity, sponsored by Orexigen Therapeutics. Started Oct 2007; status: completed.
02
Drugs
naltrexone + bupropion
03
Conditions
nicotine dependenceobesity
Beyond the preview
Go deeper on NCT00563563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00563563.